{"created":"2023-05-15T14:56:57.372337+00:00","id":77294,"links":{},"metadata":{"_buckets":{"deposit":"a7878aef-70ed-4a4c-85cf-1c3823062355"},"_deposit":{"created_by":1,"id":"77294","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"77294"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00077294","sets":["10:29"]},"author_link":["797549","797551","797552","797550"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2019-11-02","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Gastric cancer (GC) patients often already have distant metastasis at the time of diagnosis, and 4-14% of them are liver metastasis (LMGC) with dismal prognosis. Trastuzumab, a humanized anti-HER2 monoclonal antibody, is clinically used for the treatment of HER2-positive (HER2+) GC, which account for about 20% of GC. \nAlpha-radioimmunotherapy (α-RIT) is getting higher attention as a novel therapeutic option for metastasis, benefited from the combination of advantages of antibodies, cancer specific targeting, and alpha particles, high cell killing effects and short range. Astatine 211 (211At) is one of the attractiveα-emitter for clinical use. \nIn this study, we investigated the therapeutic efficacy and toxicity using preclinical HER2+ LMGC mice model and provided the proof of concept thatα-RIT with 211At-trastuzumab has high potential as a novel therapeutic option against HER2+ LMGC.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第59回日本核医学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"李, 惠子"}],"nameIdentifiers":[{"nameIdentifier":"797549","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川, 純崇"}],"nameIdentifiers":[{"nameIdentifier":"797550","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Li, Huizi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797551","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hasegawa, Sumitaka","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"797552","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"HER2高発現胃がん肝転移に対する新規アルファ線放射免疫療法","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"HER2高発現胃がん肝転移に対する新規アルファ線放射免疫療法"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-11-05"},"publish_date":"2019-11-05","publish_status":"0","recid":"77294","relation_version_is_last":true,"title":["HER2高発現胃がん肝転移に対する新規アルファ線放射免疫療法"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:53:05.245929+00:00"}